Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Department of Gynecology Oncology, Magee Women's Hospital of UPMC, Pittsburgh, PA, USA.
Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e110-e117. doi: 10.1016/j.clon.2020.08.009. Epub 2020 Sep 10.
There are limited data in endometrial cancer for nodal control and appropriate treatment volume for non-surgically resected nodes treated with chemoradiotherapy (CRT) for patients who are not candidates for upfront extrafascial hysterectomy.
Patients (n = 105) with clinical stage ≥ II endometrial cancer who were not candidates for upfront extrafascial hysterectomy treated with preoperative CRT were retrospectively reviewed. CRT included pelvic nodes to the common iliac for node-negative disease and para-aortic nodes to the renal vessel for any node-positive disease. Involved nodes most commonly received a boost of 55 Gy in 25 fractions ± additional 4-6 Gy sequential boost for nodes >2 cm.
Of the included 95 patients, 55 patients were node positive, with a total of 300 positive nodes. At a median follow-up of 25 months (interquartile range 9-46), the 3-year regional control was 91%. The 3-year involved nodal control rate was 96%. Involved nodal control was significantly higher in type I histology, nodes <2 cm and by radiation dose (75% for <55 Gy, 98% for 55 Gy in 25 fractions and 89% for >55 Gy, P = 0.03). The 3-year para-aortic failure rate for node negative patients treated with pelvis-only CRT was significantly higher with positron emission tomography/computed tomography (PET/CT) versus computed tomography (CT)-based staging (0% versus 20%).
This is the largest study examining regional control rates of involved lymph nodes with CRT for patients who were not candidates for upfront extrafascial hysterectomy. Nodal failure was low following CRT and dose ≥55 Gy in 25 fractions seems to be adequate for involved nodes.
对于因不适合进行筋膜外子宫切除术而接受放化疗(CRT)治疗的非手术切除淋巴结的子宫内膜癌患者,淋巴结控制和适当的治疗体积方面的数据有限。
回顾性分析了 105 例因不适合进行筋膜外子宫切除术而接受术前 CRT 治疗的临床分期≥Ⅱ期子宫内膜癌患者。CRT 包括对淋巴结阴性疾病进行盆腔淋巴结到髂总动脉,对任何淋巴结阳性疾病进行腹主动脉旁淋巴结到肾血管。对于>2cm 的淋巴结,最常见的是在 25 个分次中给予 55Gy 的推量±额外的 4-6Gy 序贯推量。
在纳入的 95 例患者中,55 例患者淋巴结阳性,共 300 个阳性淋巴结。在中位随访 25 个月(四分位距 9-46)时,3 年区域控制率为 91%。3 年累及淋巴结控制率为 96%。I 型组织学、淋巴结<2cm 和放射剂量(<55Gy 为 75%,25 个分次中 55Gy 为 98%,>55Gy 为 89%,P=0.03)与累及淋巴结控制率显著相关。对于仅接受盆腔 CRT 治疗的淋巴结阴性患者,与基于 CT 的分期相比,正电子发射断层扫描/计算机断层扫描(PET/CT)的 3 年腹主动脉旁失败率显著更高(0%比 20%)。
这是最大的研究,检查了不适合进行筋膜外子宫切除术的患者接受 CRT 治疗后累及淋巴结的区域控制率。CRT 后淋巴结失败率较低,25 个分次中剂量≥55Gy 似乎足以治疗累及淋巴结。